deepak1536

Munich, 29.04.2026 — The research consortium CNATM has secured its second round of funding in the German Clusters4Future program, commissioned by the Federal Ministry for Research, Technology and Space (BMFTR). As part of this pioneering translational initiative, Eisbach Bio will be developing therapeutic drugs that target cancer-driving nucleic acid regulators, supporting 𝗖𝗡𝗔𝗧𝗠’s research goals and subject focus on targeting nucleic acids. This award supports our mission to push the...

MUNICH, Germany, July 7, 2021 – Eisbach Bio, a biotechnology company targeting the molecular machines that drive human disease, today announced additional financial support from the German Ministry for Education and Research (BMBF) for the clinical development of its first-in-class SARS-CoV-2 helicase inhibitor. The total funding of EUR 8 million will support the clinical development of the Company’s novel COVID-19 therapeutic following the recent completion of its preclinical development....

The Core Facility Animal Models (CAM) of the Biomedical Center of the LMU announces a collaboration with drug discovery start-up Eisbach Bio GmbH to test SARS-CoV-2 antivirals. Eisbach has developed small molecule inhibitors which target disease-relevant and novel mechanisms in SARS-CoV-2 for the treatment of COVID-19 and is now concluding late-stage pre-clinical development together with the CAM. The CAM is conducting animal studies to evaluate the new compounds with respect to their drug...